Weekly shot may shield joints in hemophilia a patients

NCT ID NCT06752850

Ongoing Disease control Sponsor: Swedish Orphan Biovitrum Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a once-weekly medication (efanesoctocog alfa) can improve or prevent joint damage in 37 people with moderate or severe hemophilia A. Participants receive the drug for 12 months, and doctors use ultrasound and MRI to check joint health. The goal is to see if this treatment reduces swelling and lowers the risk of joint bleeds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma hemophilia hemophilia A synovitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLASSIC HEMOPHILIA HAEMOPHILIA HAEMOPHILIA A (MODERATE OR SEVERE) HEMOPHILIA HEMOPHILIA, CLASSIC SYNOVIAL HYPERTROPHY

Contacts and locations

Show contact details

Locations

Sobi Investigational Site

Milan, Italy
Sobi Investigational Site

Naples, Italy
Sobi Investigational Site

Rozzano, Italy
Sobi Investigational Site

Oslo, Norway
Sobi Investigational Site

Barcelona, Spain
Sobi Investigational Site

Madrid, Spain
Sobi Investigational Site

Seville, Spain
Sobi Investigational Site

Valencia, Spain
Sobi Investigational Site

Gothenburg, Sweden
Sobi Investigational Site

Malmö, Sweden